Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
735
archived clinical trials in
Thyroid Cancer

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Clinica Viedma
mi
from
Viedma,
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Clinica Viedma
mi
from
Viedma,
Click here to add this to my saved trials
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated:  10/27/2015
Clinical Research Facility
mi
from
Houston, TX
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated: 10/27/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated:  10/27/2015
Investigational Site Number 203002
mi
from
Olomouc,
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated: 10/27/2015
Investigational Site Number 203002
mi
from
Olomouc,
Click here to add this to my saved trials
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated:  11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated: 11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
Status: Enrolling
Updated:  11/27/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
Status: Enrolling
Updated: 11/27/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study
The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study
Status: Enrolling
Updated:  3/28/2016
Boston Med Ctr
mi
from
Boston, MA
The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study
The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study
Status: Enrolling
Updated: 3/28/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in
Status: Enrolling
Updated:  4/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in
Status: Enrolling
Updated: 4/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Status: Enrolling
Updated:  6/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Status: Enrolling
Updated: 6/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid
Status: Enrolling
Updated:  12/20/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid
Status: Enrolling
Updated: 12/20/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated:  3/7/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated: 3/7/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated:  3/7/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated: 3/7/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated:  3/7/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated: 3/7/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated:  3/7/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated: 3/7/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated:  3/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated: 3/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated:  3/7/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated: 3/7/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated:  3/7/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Status: Enrolling
Updated: 3/7/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated:  4/9/2018
University of California, San Diego
mi
from
San Diego, CA
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated: 4/9/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated:  4/9/2018
University of Chicago Medical Center
mi
from
Chicago, IL
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated: 4/9/2018
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated:  4/9/2018
Massachusetts General Hospital, Harvard Medical School
mi
from
Boston, MA
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated: 4/9/2018
Massachusetts General Hospital, Harvard Medical School
mi
from
Boston, MA
Click here to add this to my saved trials
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated:  4/9/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated: 4/9/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated:  4/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status: Enrolling
Updated: 4/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials